Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


MHRA (UK) approves Jemperli (dostarlimab), a treatment for some types of endometrial cancer in adults – GSK

Written by | 11 Oct 2023 | Obstetrics & Gynaecology

The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised a new indication for Jemperli (dostarlimab), a treatment for some types of endometrial cancer in adults. It can be used to treat patients that have a tumour abnormality called mismatch repair deficient (dMMR) / microsatellite instability-high (MSI-H) when the cancer is at an advanced stage when first diagnosed or has returned after previous treatment. Endometrial cancer is a cancer of the womb (uterus) lining and can occur in any person with a womb, although it’s most common in those who have been through the menopause.

Jemperli is now authorised to be used together with chemotherapy to slow the progression of these cancers, increasing life expectancy for patients. This is the first medicine licensed as first line treatment for primary advanced or recurrent endometrial cancer.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.